Tech Company Financing Transactions
Gen9 Funding Round
Agilent Technologies invested in a $21 million funding round for Gen9. The funding round was announced on 4/25/2013.
Transaction Overview
Company Name
Announced On
4/25/2013
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Gen9 will use these funds to further invest in product development and to expand the commercial infrastructure for its synthetic biology business.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
840 Memorial Dr. 5th Floor
Cambridge, MA 01239
USA
Cambridge, MA 01239
USA
Phone
Website
Email Address
Overview
Don t waste time picking colonies. Gen9 s innovative process provides sequence-perfect, clonal gene synthesis products at the best price in the industry.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Munnelly
Chief Financial Officer
David Stone
VP - Bus. Development
Aaron Zucker
VP - Marketing
Leda Notchey
VP - R & D
Devin Leake
Browse more venture capital transactions:
Prev: 4/25/2013: SkyKick venture capital transaction
Next: 4/26/2013: EV Connect venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs